Capturing changes in gene expression dynamics by gene set differential coordination analysis

Genomics

Volumn 98, Issue 6, 2011, Pages 469-477

  Yu, Tianwei ^a   Bai, Yun ^b  

^a EMORY UNIVERSITY   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Gene expression; Gene set analysis; Microarray

Indexed keywords

TRANSCRIPTOME;

ARTICLE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SET DIFFERENTIAL COORDINATION ANALYSIS; GENETIC ANALYSIS; GENETIC HETEROGENEITY; LINKAGE ANALYSIS; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL;

COMPUTER SIMULATION; DATABASES, GENETIC; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTOME;

EID: 81955161934     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2011.09.001     Document Type: Article

References (50)

1. Nam D., Kim S.Y. Gene-set approach for expression pattern analysis. Brief. Bioinform. 2008, 9:189-197.
2. Efron B., Tibshirani R. On testing the significance of sets of genes. Ann. Appl. Stat. 2007, 1:107-129.
3. Keller A., Backes C., Gerasch A., Kaufmann M., Kohlbacher O., Meese E., Lenhof H.P. A novel algorithm for detecting differentially regulated paths based on gene set enrichment analysis. Bioinformatics 2009, 25:2787-2794.
4. Luo W., Friedman M.S., Shedden K., Hankenson K.D., Woolf P.J. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 2009, 10:161.
5. Oron A.P., Jiang Z., Gentleman R. Gene set enrichment analysis using linear models and diagnostics. Bioinformatics 2008, 24:2586-2591.
6. Chen X., Wang L., Smith J.D., Zhang B. Supervised principal component analysis for gene set enrichment of microarray data with continuous or survival outcomes. Bioinformatics 2008, 24:2474-2481.
7. Wu M.C., Zhang L., Wang Z., Christiani D.C., Lin X. Sparse linear discriminant analysis for simultaneous testing for the significance of a gene set/pathway and gene selection. Bioinformatics 2009, 25:1145-1151.
8. Tsai C.A., Chen J.J. Multivariate analysis of variance test for gene set analysis. Bioinformatics 2009, 25:897-903.
9. Bussemaker H.J., Ward L.D., Boorsma A. Dissecting complex transcriptional responses using pathway-level scores based on prior information. BMC Bioinformatics 2007, 8(Suppl 6):S6.
10. Goeman J.J., Buhlmann P. Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics 2007, 23:980-987.
11. Watson M. CoXpress: differential co-expression in gene expression data. BMC Bioinformatics 2006, 7:509.
12. Montaner D., Minguez P., Al-Shahrour F., Dopazo J. Gene set internal coherence in the context of functional profiling. BMC Genomics 2009, 10:197.
13. Ihmels J., Levy R., Barkai N. Principles of transcriptional control in the metabolic network of Saccharomyces cerevisiae. Nat. Biotechnol. 2004, 22:86-92.
14. Choi Y., Kendziorski C. Statistical methods for gene set co-expression analysis. Bioinformatics 2009, 25:2780-2786.
15. Cho S.B., Kim J., Kim J.H. Identifying set-wise differential co-expression in gene expression microarray data. BMC Bioinformatics 2009, 10:109.
16. Yu T., Sun W., Yuan S., Li K.C. Study of coordinative gene expression at the biological process level. Bioinformatics 2005, 21:3651-3657.
17. Li K.C., Liu C.T., Sun W., Yuan S., Yu T. A system for enhancing genome-wide coexpression dynamics study. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15561-15566.
18. Yu T., Li K.C. Inference of transcriptional regulatory network by two-stage constrained space factor analysis. Bioinformatics 2005, 21:4033-4038.
19. Comaniciu D., Ramesh V., Meer P. Kernel-based object tracking. IEEE Trans. Pattern Anal. Mach. Intell. 2003, 25:564-577.
20. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., Harris M.A., Hill D.P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
21. Spellman P.T., Sherlock G., Zhang M.Q., Iyer V.R., Anders K., Eisen M.B., Brown P.O., Botstein D., Futcher B. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol. Biol. Cell 1998, 9:3273-3297.
22. Staudt L.M., Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol. 2005, 87:163-208.
23. Barrett T., Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol. 2006, 411:352-369.
24. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer-current status and future directions. Ann. Oncol. 2009, 20:1913-1927.
25. Benjamini Y., Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 2001, 29:1165-1188.
26. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
27. Graeser M., McCarthy A., Lord C.J., Savage K., Hills M., Salter J., Orr N., Parton M., Smith I.E., Reis-Filho J.S., Dowsett M., Ashworth A., Turner N.C. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 2010, 16:6159-6168.
28. Teschendorff A.E., Miremadi A., Pinder S.E., Ellis I.O., Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007, 8:R157.
29. Tommiska J., Bartkova J., Heinonen M., Hautala L., Kilpivaara O., Eerola H., Aittomaki K., Hofstetter B., Lukas J., von Smitten K., Blomqvist C., Ristimaki A., Heikkila P., Bartek J., Nevanlinna H. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008, 27:2501-2506.
30. Thomas G., Jacobs K.B., Kraft P., Yeager M., Wacholder S., Cox D.G., Hankinson S.E., Hutchinson A., Wang Z., Yu K., Chatterjee N., Garcia-Closas M., Gonzalez-Bosquet J., Prokunina-Olsson L., Orr N., Willett W.C., Colditz G.A., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Diver R., Prentice R., Jackson R., Kooperberg C., Chlebowski R., Lissowska J., Peplonska B., Brinton L.A., Sigurdson A., Doody M., Bhatti P., Alexander B.H., Buring J., Lee I.M., Vatten L.J., Hveem K., Kumle M., Hayes R.B., Tucker M., Gerhard D.S., Fraumeni J.F., Hoover R.N., Chanock S.J., Hunter D.J. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 2009, 41:579-584.
31. Greenberg S., Rugo H.S. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010, 16:33-38.
32. Requena L., Sangueza M., Sangueza O.P., Kutzner H. Pigmented mammary Paget disease and pigmented epidermotropic metastases from breast carcinoma. Am. J. Dermatopathol. 2002, 24:189-198.
33. Azzato E.M., Tyrer J., Fasching P.A., Beckmann M.W., Ekici A.B., Schulz-Wendtland R., Bojesen S.E., Nordestgaard B.G., Flyger H., Milne R.L., Arias J.I., Menendez P., Benitez J., Chang-Claude J., Hein R., Wang-Gohrke S., Nevanlinna H., Heikkinen T., Aittomaki K., Blomqvist C., Margolin S., Mannermaa A., Kosma V.M., Kataja V., Beesley J., Chen X., Chenevix-Trench G., Couch F.J., Olson J.E., Fredericksen Z.S., Wang X., Giles G.G., Severi G., Baglietto L., Southey M.C., Devilee P., Tollenaar R.A., Seynaeve C., Garcia-Closas M., Lissowska J., Sherman M.E., Bolton K.L., Hall P., Czene K., Cox A., Brock I.W., Elliott G.C., Reed M.W., Greenberg D., Anton-Culver H., Ziogas A., Humphreys M., Easton D.F., Caporaso N.E., Pharoah P.D. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J. Natl. Cancer Inst. 2010, 102:650-662.
34. Yuan K., Frolova N., Xie Y., Wang D., Cook L., Kwon Y.J., Steg A.D., Serra R., Frost A.R. Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues. J. Histochem. Cytochem. 2010, 58(10):857-870.
35. Dey J.H., Bianchi F., Voshol J., Bonenfant D., Oakeley E.J., Hynes N.E. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010, 70:4151-4162.
36. Descamps S., Toillon R.A., Adriaenssens E., Pawlowski V., Cool S.M., Nurcombe V., Le Bourhis X., Boilly B., Peyrat J.P., Hondermarck H. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J. Biol. Chem. 2001, 276:17864-17870.
37. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9:873-886.
38. Taylor K.M. A distinct role in breast cancer for two LIV-1 family zinc transporters. Biochem. Soc. Trans. 2008, 36:1247-1251.
39. Sorich M.J., Pottier N., Pei D., Yang W., Kager L., Stocco G., Cheng C., Panetta J.C., Pui C.H., Relling M.V., Cheok M.H., Evans W.E. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008, 5:e83.
40. Wessels J.A., Huizinga T.W., Guchelaar H.J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:249-255.
41. Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 2009, 36(Suppl 3):S3-S17.
42. Teachey D.T., Sheen C., Hall J., Ryan T., Brown V.I., Fish J., Reid G.S., Seif A.E., Norris R., Chang Y.J., Carroll M., Grupp S.A. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008, 112:2020-2023.
43. Boukhettala N., Leblond J., Claeyssens S., Faure M., Le Pessot F., Bole-Feysot C., Hassan A., Mettraux C., Vuichoud J., Lavoinne A., Breuille D., Dechelotte P., Coeffier M. Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E182-E190.
44. Shemon A.N., Sluyter R., Wiley J.S. Rottlerin inhibits P2X(7) receptor-stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes. Immunol. Cell Biol. 2007, 85:68-72.
45. Jaskiewicz K., Voigt H., Blakolmer K. Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J. Toxicol. Clin. Toxicol. 1996, 34:301-305.
46. Jaksic O., Kardum-Skelin I., Jaksic B. Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives. Coll. Antropol. 2010, 34:309-313.
47. Dubielecka P.M., Jazwiec B., Potoczek S., Wrobel T., Miloszewska J., Haus O., Kuliczkowski K., Sikorski A.F. Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem. Pharmacol. 2005, 69:73-85.
48. Smolenska Z., Kaznowska Z., Zarowny D., Simmonds H.A., Smolenski R.T. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:997-1002.
49. Zaza G., Cheok M., Yang W., Panetta J.C., Pui C.H., Relling M.V., Evans W.E. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005, 106:1778-1785.
50. Killcoyne S., Carter G.W., Smith J., Boyle J. Cytoscape: a community-based framework for network modeling. Methods Mol. Biol. 2009, 563:219-239.